Fatigue News and Research RSS Feed - Fatigue News and Research

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen today announced that it will present data from multiple Kyprolis (carfilzomib) for Injection, BLINCYTO (blinatumomab), oprozomib and Nplate (romiplostim)‎ studies at the 20th Congress of the European Hematology Association taking place in Vienna, June 11 - 14, 2015. [More]
Salix Pharmaceuticals receives FDA approval for Xifaxan 550 mg to treat IBS-D in adults

Salix Pharmaceuticals receives FDA approval for Xifaxan 550 mg to treat IBS-D in adults

Valeant Pharmaceuticals International, Inc. announced that its wholly owned subsidiary, Salix Pharmaceuticals, Inc., has received approval from the U.S. Food and Drug Administration for Xifaxan 550 mg for the treatment of IBS-D in adults. [More]
New Health Union study finds severe impact of rheumatoid arthritis on patients' quality of life

New Health Union study finds severe impact of rheumatoid arthritis on patients' quality of life

In a new national survey of rheumatoid arthritis (RA) patients, Health Union found a severe impact on quality of life, employment, and ability to afford treatment. The autoimmune condition attacks the body, resulting in joint inflammation, pain, stiffness, and swelling, but may also harm other organs. About 1.3 million Americans or about one percent of the global population have RA. [More]
Study reveals how attitudes, beliefs of cancer patients drive complementary and alternative medicine use

Study reveals how attitudes, beliefs of cancer patients drive complementary and alternative medicine use

A new study has shed light on how cancer patients' attitudes and beliefs drive the use of complementary and alternative medicine. Published early online in CANCER, a peer-reviewed journal of the American Cancer Society, the findings may help hospitals develop more effective and accessible integrative oncology services for patients. [More]
Esophageal cancer patients treated with proton therapy experience less toxic side effects

Esophageal cancer patients treated with proton therapy experience less toxic side effects

New research by scientists at the University of Maryland School of Medicine has found that esophageal cancer patients treated with proton therapy experienced significantly less toxic side effects than patients treated with older radiation therapies. [More]
RCC benefit independent of sorafenib, sunitinib sequence order

RCC benefit independent of sorafenib, sunitinib sequence order

Sequential treatment with sorafenib followed by sunitinib is not superior to sunitinib followed by sorafenib in patients with advanced or metastatic renal cell carcinoma, suggests research published in European Urology. [More]
Healthy Delights launches five new products in GNC stores nationwide

Healthy Delights launches five new products in GNC stores nationwide

Healthy Delights®, the leaders in confectionary nutritional products, is proud to launch five new products in GNC stores nationwide: Probiotic Chocolate Bites, Probiotic Greek Yogurt Bites, Turmeric Curcumin Chews, Magnesium Chews, and Cranberry Chews. [More]
Investing in new hepatitis C therapies may have significant economic impact

Investing in new hepatitis C therapies may have significant economic impact

While a new generation of safer, more effective oral medications to treat hepatitis C patients may cost tens of thousands of dollars for a 12-week regiment, investing in these new therapies could generate savings estimated at more than $3.2 billion annually in the U.S. and five European countries, according to a new study (abstract 228) released today at Digestive Disease Week® (DDW) 2015. [More]
UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB sponsoring several presentations on Cimzia for Crohn's disease at DDW 2015

UCB, a global biopharmaceutical company focusing on immunology and neurology treatment and research, is sponsoring several data presentations on Cimzia (certolizumab pegol) at Digestive Disease Week 2015, taking place in Washington, DC from May 16-19. [More]
Combination therapy provides promising results in patients with advanced non-small cell lung cancer

Combination therapy provides promising results in patients with advanced non-small cell lung cancer

An early phase study testing an anti-PDL1 agent in combination with standard chemotherapy in the treatment of advanced non-small cell lung cancer has provided promising early results, prompting multiple phase III studies in lung cancer. The findings are being presented at the annual meeting of the American Society of Clinical Oncology. [More]
Simple blood tests diagnose irritable bowel syndrome quickly and accurately

Simple blood tests diagnose irritable bowel syndrome quickly and accurately

Millions of people afflicted by irritable bowel syndrome can now be diagnosed quickly and accurately with two simple blood tests developed by a Cedars-Sinai gastroenterologist. [More]
New Johns Hopkins Lyme Disease Clinical Research Center launched

New Johns Hopkins Lyme Disease Clinical Research Center launched

Fundamental research into the causes and cures of post-treatment Lyme disease syndrome now has its first home base at a major U.S. medical research center with the launch of the Johns Hopkins Lyme Disease Clinical Research Center. Inaugurated on May 12, 2015, with a major gift from the Lyme Disease Research Foundation, the center plans an ambitious research program targeting this increasingly common disease, which costs the U.S. economy up to $1.3 billion per year in treatment costs alone. [More]
FDA licenses Protein Sciences' Pearl River, NY facility to manufacture Flublok influenza vaccine

FDA licenses Protein Sciences' Pearl River, NY facility to manufacture Flublok influenza vaccine

Protein Sciences Corporation announced that on May 12, 2015 the U.S. Food and Drug Administration licensed its Pearl River, NY manufacturing facility for the commercial manufacturing of Flublok influenza vaccine. Flublok is the world's first licensed influenza vaccine made using modern recombinant technology. [More]
Global survey finds gap in physicians' understanding on impact of lupus on patients' lives

Global survey finds gap in physicians' understanding on impact of lupus on patients' lives

As many people in the lupus community prepare to come together in support of World Lupus Day (May 10), a global survey shows that systemic lupus erythematosus (SLE) patients have difficulty describing their symptoms to their physicians, which leads to a gap in physicians understanding the full impact the illness has on patients' lives. [More]
STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

STA, Helsinn announce approval of AKYNZEO for prevention of chemotherapy-induced CINV

Australian biopharmaceutical company Specialised Therapeutics Australia and Helsinn, a Swiss group focused on building quality cancer care, announce that the Therapeutic Goods Administration has approved AKYNZEO for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy. [More]
Obesity and depression play role in excessive daytime sleepiness

Obesity and depression play role in excessive daytime sleepiness

Obesity and depression -- not only lack of sleep -- are underlying causes for regular drowsiness, according to Penn State College of Medicine researchers. They say these findings could lead to more personalized sleep medicine for those with excessive daytime sleepiness (EDS). [More]
CHOP's patient safety team recognized for work alarm fatigue in hospital units

CHOP's patient safety team recognized for work alarm fatigue in hospital units

A patient safety team at The Children's Hospital of Philadelphia who analyzed the problem of alarm fatigue in hospital units has been recognized for the best research paper of 2014 in a journal dedicated to biomedical technology. [More]
ViiV Healthcare initiates Phase III trial to evaluate dolutegravir and rilpivirine in HIV patients

ViiV Healthcare initiates Phase III trial to evaluate dolutegravir and rilpivirine in HIV patients

ViiV Healthcare today announced the start of a Phase III clinical trial programme to evaluate the safety and efficacy of dolutegravir (Tivicay) and rilpivirine (Edurant) as maintenance therapy for adult patients with HIV. [More]
1 in 5 people to develop heart failure in developed countries

1 in 5 people to develop heart failure in developed countries

One person in five is expected to develop heart failure in developed countries, a disease with no cure but which is largely preventable. [More]
Protein Sciences, CTH@H to provide Flublok vaccine to home health and hospice agencies in Connecticut

Protein Sciences, CTH@H to provide Flublok vaccine to home health and hospice agencies in Connecticut

Protein Sciences Corporation, along with The Connecticut Association for Healthcare at Home, announced a new partnership today that will bring Flublok influenza vaccine to home health and hospice agencies across the state. As a new affinity partner of CTH@H, Protein Sciences will make Flublok available to CTH@H member agencies for the 2015/16 flu season. [More]
Advertisement
Advertisement